Sabrina Serani

Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.

The rate of disease progression among patients with low- or intermediate-risk myelofibrosis appeared to increase over time in the MOST study.

Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Disease-free survival benefits with chemotherapy appears to be more prominent in patients with colorectal cancer who are minimal residual disease–positive compared with those minimal residual disease–negative disease.

Data from the phase 2 KRYSTAL-7 study support a phase 3 trial assessing concurrent adagrasib plus pembrolizumab compared with pembrolizumab alone in treatment-naïve KRAS G12C-mutated non–small cell lung cancer.